STEERLife, the life sciences arm of STEER World, is transforming the landscape of potent and complex drug development through sustainable, continuous processing technology. This breakthrough addresses one of the most demanding sectors in pharmaceutical science.

At the core of STEERLife’s innovation is its proprietary solvent-free melt fusion technology, a continuous manufacturing platform that avoids the use of harmful organic solvents. Engineered for high-potency and difficult-to-formulate molecules, the platform enhances safety, scalability, and formulation efficiency.

Functioning as a modern Contract Research, Development, and Manufacturing Organization (CRDMO), STEERLife supports the development of a wide range of complex drugs—including New Chemical Entities (NCEs), hormone treatments, orphan drugs, complex generics (ANDAs), and 505(b)(2) products. The company uses a process-focused approach to help global pharmaceutical companies overcome formulation and production challenges.

“Our continuous, solvent-free process is not just about meeting standards—it’s about delivering speed, precision, and sustainability for the world’s toughest therapies,” said Indu Bhushan, CEO & Director at STEERLife.

Several key drug development projects are already underway, with launches planned from 2026 onwards. These include generic versions of leading medications such as Erleada, Xtandi, Venclexta, and Lynparza.

With strategic partnerships and global outreach—including the U.S., Europe, MENA, and Southeast Asia—STEERLife is leading India's shift from batch production to continuous processing, helping pharma companies reduce timelines, raise quality standards, and enable next-generation drug delivery.